CETP as a Therapeutic Target

1.5 ACPE 1.5 ANCC Contract Hours 1.5 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Philip Barter, MD, PhD

Philip Barter, MD, PhD
Director, The Heart Research Institute
Professor of Medicine, University of Sydney
Sydney, Australia

Philip Barter is a senior researcher and former director of the Heart Research
Institute in Sydney. He is also a Professor of Medicine at the University of
Sydney. He graduated in medicine from the University of Adelaide and gained
his PhD from the Australian National University. He is a fellow of the Royal
Australasian College of Physicians. He is currently President Elect of the
International Atherosclerosis Society. He is also a member of the International
Task Force for Prevention of Coronary Heart Disease and is a member of the
executive of the International Chair on Cardiometabolic Risk. He was the
2011 recipient of the Anitschkow Award of the European Atherosclerosis
Society. He has previously held positions in research institutes and
universities in Australia and the US. His basic research interests are plasma
lipids and lipoproteins, specifically high density lipoproteins, the factors that
regulate them and the mechanism by which they protect against
cardiovascular disease. His clinical research involves participation in clinical
trials of lipid-lowering agents. He was a member of the steering committees of
the FIELD study, the TNT Study, was co-chair of steering committee of the
DEFINE study and was chairman of the steering committee of the
ILLUMINATE trial. He is currently a member of the steering committees of the
REVEAL HPS-3 TIMI-55 trial and the ACCELERATE trial; these are two
large-scale clinical outcome trials assessing the ability of new CETP inhibitors
to reduce CV risk. He has published more than 300 peer-reviewed research
papers on plasma lipids and lipoproteins, their metabolism, regulation,
function and relationship to atherosclerosis. He has also written handbooks on
HDL and CETP inhibitors. Recognizing that atherosclerosis has become a
major global epidemic, he is committed to the development of atherosclerosis
research and education programs in countries beyond North America and
Western Europe, including South and Southeast Asia, South and Central
America, the Middle East and Africa.

John J.P. Kastelein, MD PhD, FESC

John J.P. Kastelein, MD PhD, FESC
Professor of Medicine
Dept. of Vascular Medicine
Academic Medical Center / University of Amsterdam
Amsterdam, The Netherlands

John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease.
He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr. M.R. Hayden.
Upon his return to the Netherlands, he was awarded a doctorate (Cum Laude) and in 1989 he founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam, which has become part of the department of Vascular Medicine. Last year, he received the Lifetime Achievement Award of the Dutch Heart Foundation (1x €106) and was awarded a CVON grant for 5x €106.
In 1995, Dr. Kastelein set up a foundation for the active identification of patients with classical familial hypercholesterolaemia (FH) in the Netherlands (StoeH), for which he currently holds a position in the board of directors. This program has now been fully institutionalized and is financially supported by the Ministry of Health with a total grant of approximately 30 million Euros. Since its inception, the StoeH has identified over 27.000 individuals for whom a molecular diagnosis of FH could be made. The subsequent improvement of the treatment of these FH carriers has saved many lives, as published in Lancet in 2001 and very recently in the British Medical Journal in 2008.
In 1997 and 1998 he served a visiting Professorship at the Center for Molecular Medicine and Therapeutics at the University of British Columbia, Vancouver, Canada. In these years, Dr. Kastelein was a co-founder of Xenon Genetics Inc., a drug discovery company that has now changed its name into Xenon Pharmaceuticals Inc. and is based in Vancouver, Canada.
Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology.
Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008.
Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment of  hypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease.
He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72.  
Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease.
Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet.
Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has lead to the recognition of the AMC as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the set up of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject. Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal.
He has directed 47 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators


Professor of Cardiology
SAHMRI Heart Foundation Heart Disease Theme Leader
South Australian Health & Medical Research Institute
Adelaide, SA

Stephen Nicholls is Professor of Cardiology at the University of Adelaide and the inaugural SAHMRI Heart Foundation Heart Disease Theme Leader at the South Australian Health & Medical Research Institute. Steve undertook his medical degree at the University of Adelaide and completed his medical residency at the Royal Adelaide Hospital. Following advanced training in cardiovascular medicine in Newcastle, he undertook doctoral studies at the Royal Adelaide Hospital and Heart Research Institute focusing on the anti-inflammatory properties of HDL.
He subsequently moved to the Cleveland Clinic to undertake postdoctoral studies of novel imaging modalities of atherosclerotic plaque, supported by the Ralph Reader Overseas Research Fellowship of the National Heart Foundation. He was promoted to dual faculty appointments in the departments of Cell Biology and Cardiovascular Medicine, where he held the positions of Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research and the Medical Director of the Atherosclerosis Imaging Core Laboratory and Assistant Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
He has published more than 370 original manuscripts, conference proceedings and book chapters in journals including the New England Journal of Medicine, JAMA, Lancet and Nature Medicine. He has published two books in the field of cardiovascular medicine. He is the recipient of the Young Investigator Award of the 2003 International Symposium of Atherosclerosis and was a finalist for the Samuel A. Levine Clinical Young Investigator Award at the 2005 Annual Scientific Sessions of the American Heart Association. His research interests span the translational spectrum from the factors influencing the biological activity of HDL, through to development and use of novel plaque imaging modalities and ultimately large scale clinical trials of antiatherosclerotic therapies. He currently is a member of the editorial boards of the European Journal of Preventive Cardiology, Journal of the American College of Cardiology, JACC: Cardiovascular Imaging and Arteriosclerosis, Thrombosis and Vascular Biology.
He has recently returned to Adelaide to establish the translational cardiovascular research program at SAHMRI. In his spare time he likes to consider himself an avid, albeit awkward runner.
1. Explain current research defining the mechanisms underlying cholesteryl ester transfer protein (CETP) inhibition and its impact on HDL metabolism
2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families